Ask HopeStage to review this study with me
Study ID: NCT05169710. We help you review the study, but cannot decide medical eligibility.
TerminatedNCT05169710
An Investigational Drug for depression
This study has public registry information in the United States, in Canada, in Bulgaria, .... It is testing an Investigational Drug for depression.
Depression, BipolarityDrugFrom 18 Years to 65 Years
Key information made simple
What is this study testing?
This study is testing whether an Investigational Drug may be useful for adults experiencing depression.
What would participation involve?
Participants may receive an Investigational Drug, attend study visits with the research team. The registry lists locations in Bulgaria, Canada, Japan.
Who is it mainly for?
This study appears to be mainly for adults with depression.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a hospital, with sites including University of Alabama at Birmingham Huntsville Regional Medical Campus, Sanro Clinical Research Group LLC in Bryant, and Advanced Research Center, Inc in Anaheim. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include other factors that could make participation unsuitable and other treatments that could interfere with the study. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: December 21, 2021
- Recruitment status
- Terminated
- Estimated enrollment
- Not clearly listed
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States, Canada, Bulgaria, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05169710
- Official title
- A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolarity type I.
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT05169710. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Bulgaria.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring digital app or tool for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Who might this study be for?
This study may concern people with depression; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Sumitomo Pharma America, Inc., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is not currently recruiting. Check the official registry for the reason and latest status.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
TerminatedNCT02389712
16-week Comparative Effectiveness study of Lamotrigine vs. Fluoxetine for Depression in bipolarity
This study has public registry information. It focuses on bipolarity and currently lists study information in the United States.
TerminatedNCT05227209
Safety study of an Investigational Drug in depression
This study has public registry information in the United States, in Bulgaria, and in Japan. It is testing an Investigational Drug for depression.
TerminatedNCT00535262
A Study Assessing EmSam in Depression in bipolarity
This study has public registry information. It focuses on bipolarity and currently lists study information in the United States.